Chelsea Therapeutics Extends Cash Runway, Raises $35M
By Catherine Shaffer
Tuesday, February 22, 2011
After extending and restructuring its Phase III trial of Northera (droxidopa) for neurogenic orthostatic hypotension (NOH) in Parkinson's patients, Chelsea Therapeutics Inc. needed a bit more of a cash boost to carry it through to launch.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.